Navigation Links
John Theurer Cancer Center brings leading experts for its Ninth Annual Neuro-Oncology Symposium
Date:5/9/2013

al Sloan-Kettering Cancer Center: The Emerging Molecular Foundations of Diffuse Gliomas
  • Michael Vogelbaum, M.D., Ph.D., Associate Director, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation: Surgery for Gliomas: How Far Should We Go?

    "It's an exciting time for neuro-oncology at our Brain and Spine Institute," said Chief Emeritus Mark S. Pascal, M.D. "Recently we have seen tremendous programmatic growth, including in our Gamma Knife radiosurgery center, robust clinical trial program, and dedicated support services for neuro-oncology patients."

    The conference will be held at John Theurer Cancer Center, 92 Second Street, Hackensack, NJ 07601. HackensackUMC designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credit(s), physicians should only claim credits commensurate with the extent of their participation in the activity. This conference is complimentary but advanced registration is required. To register or for more information, please contact Maryann V. Lederhilger at 551-996-1162 or mlederhilger@HackensackUMC.org.

    "Oncology is moving at an accelerated pace," said Andre Goy, M.D., M.S., Chairman and Director, Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation at Regional Cancer Care Associates. "We believe it is more important than ever to help physicians and healthcare professional stay up to date with the latest research and treatment best practices."

    "John Theurer Cancer Center is committed to helping healthcare professionals gain access to, and knowledge of, the latest advancements in cancer care, and we are proud to offer continuing education programs like the neuro-oncology symposium to help fulfill this goal," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor, and Vice President of Cancer Services and President of Regional Cancer
    '/>"/>


  • Contact: Amy Leahing
    aleahing@p4strategy.com
    646-476-3845
    John Theurer Cancer Center
    Source:Eurekalert

    Page: 1 2 3

    Related medicine news :

    1. John Theurer Cancer Center hosts first Womens Oncology Conference
    2. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
    3. John Theurer Cancer Center researchers shed light on new multiple myeloma therapy
    4. Experts from John Theurer Cancer Center to participate in the AAMDSIF Patient and Family Conference
    5. John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium
    6. Research finds identifies social needs of young people with cancer
    7. Popular diabetes drug does not improve survival rates after cancer: Study
    8. Your immune system: On surveillance in the war against cancer
    9. Fun and friends help ease the pain of breast cancer
    10. Missouri Man Alleges Five Years of Actos Use Caused his Bladder Cancer; Parker Waichman LLP Files Lawsuit on Victim’s Behalf
    11. Just How Might Exercise Lower Breast Cancer Risk?
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... Flagstaff, AZ (PRWEB) July 31, 2014 ... long-term substance abuse treatment program in Flagstaff, AZ, learn ... an understanding of equipment and paddle strokes in preparation ... Juan River. , "I think that [the kayaking course] ... things that they struggle with in their early part ...
    (Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... closure in front of an enthusiastic audience of international ... Trichophytic Closure improves the appearance of a patient’s ... results of this procedure are minimally detectable in most ... technique improves on the original method of donor wound ...
    (Date:7/31/2014)... July 31, 2014 Located on one of ... Macy’s, The Rothenberg Law Firm LLP has moved its office ... , The Rothenberg Law Firm has been handling catastrophic personal ... spurred by growth in the firm’s continued success in seeking ... New York office has a team of experienced and successful ...
    (Date:7/31/2014)... To further educate the public, The Rothenberg Law ... information regarding leaving children in hot vehicles: , Leaving ... Because a child’s body can heat up three to ... alone in a hot vehicle puts them at extreme ... of Children Left Alone in a Car , According ...
    (Date:7/31/2014)... Village, IL (PRWEB) July 31, 2014 ... solutions, today announced a new sponsorship of the ... and center are Etymotic’s hearing protection products ETY•Plugs® ... while protecting against the harmful effects of high-level ... off the sponsorship at the Drum Corps International ...
    Breaking Medicine News(10 mins):Health News:Back2Basics Substance Abuse Residents Take Kayaking Class for the First Time 2Health News:Novel Technique in Wound Closure Delivers More Discreet Results in Hair Transplant Patients 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2
    ... resident Daniel Alford, MD, an associate professor of medicine ... in the General Internal Medicine Department at Boston Medical ... Abuse Prevention and Treatment Division with the Boston Public ... nation to receive the Nyswander-Dole Award. The award was ...
    ... ViroPharma Incorporated,(Nasdaq: VPHM ) reported today its financial results for ... since June 30, 2007 include:, Clinical:, -- Patient enrollment ... in liver transplant patients; -- Patient enrollment continued ... stem cell transplant patients; study enrollment expanded to ...
    ... Inc.,(Pink Sheets: HRAL) announced that it has received additional ... International, Inc.,(NYSE: WMT ), to open their ninth ... Wal-Mart Store #3195 located at 1070 Major,Mackenzie Drive in ... #7 Unit Y006A in Markham will both officially open ...
    ... Revenue and EPS Guidance; Provides Preliminary ... 2008 Guidance ... AM ET, BATON ROUGE, La., Oct 30 Amedisys, Inc.,(Nasdaq: AMED ... reported its financial results for the,third quarter ended September 30, 2007: Three-Month ...
    ... FREISING-WEIHENSTEPHAN, Germany, October 30 Pieris ... Netherlands) today,announced the commencement of a ... for G-Protein Coupled Receptors (GPCRs) and ... has pioneered Anticalins(R) as next generation ...
    ... Inc. (NYSE: CRY ),a biomaterials, medical device and ... been named vice president, clinical research,effective October 29, 2007. ... of CryoLife Europa, Ltd., based in the U.K., since ... has held several positions with,the Company including project director ...
    Cached Medicine News:Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 2Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 2Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 3Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 4Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 5Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 6Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 7Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 8Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 9Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 10Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 11Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 12Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 13Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 14Health News:Amedisys Reports Record Third Quarter Revenue and Earnings 15Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 2Health News:Pieris and Pepscan to Identify GPCR-Specific Anticalins(R) Using CLIPS(TM) Protein Mimicry Technology 3Health News:CryoLife Announces Additions to Management Team 2
    (Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
    (Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
    (Date:7/31/2014)... 31, 2014 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... initiated the development of its lead molecule, Anatabine Citrate, ... has selected Quotient Clinical, The Translational Pharmaceutics Company, based ... to run its early development programs. The ... by the end of the third quarter with the ...
    Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
    ... 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced,follow-up ... of GVAX immunotherapy,for pancreatic cancer which was ... Center. The trial enrolled 60 patients with,operable ... of their tumor and adjuvant radiation and,chemotherapy. ...
    ... 2002 , CHICAGO/DARMSTADT, Germany, June 4, 2007 – ... the American Society of,Clinical Oncology (ASCO) annual meeting ... patients with newly diagnosed,glioblastoma – a particularly aggressive ... integrin inhibitor targeting the,tumor and its vasculature. , ...
    Cached Medicine Technology:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 2Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 3Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 4Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 5Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
    eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
    Wire mesh braided design with a platinum core....
    ... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
    ... The Libert Coronary Stent ... generation of lesion access ... flexibility, a low crossing ... delivery catheter, the performance ...
    Medicine Products: